Columbia University DKV | New York Academy of Sciences | Mailman School of Public Health | NIAID
Home Feedback | About | print Print | Help
Latest Headlines
Executive Summary
Topics and Speakers
Coronavirus Biology and Pathogenesis
On the Front Lines
Approaches to Vaccines and Drug Development
Blocking SARS Virus Fusion
Lessons in Interventions for SARS
Status of Drug Screening vs. SARS
Adenovirus Vector Technologies for Vaccines
Some Approaches to Vaccine Development
Panel 3 Discussion
Future Perspectives on Emerging Infections
References and Resources
pdf Conference Transcript
pdf Conference Highlights
SARS in the Context of Emerging Infectious Threats SARS in the Context of Emerging Infectious Threats
Approaches to Vaccines and Drug Development
Blocking SARS Virus Fusion

David Ho, Aaron Diamond AIDS Research Center, New York
Play Video Read Transcript
View SlidesView Slides | References | Biography | Contact


Visit to China
• The concern among people and the socioeconomic impact are high in China.
• China recognizes that it missed opportunities to address SARS more effectively and is now galvanized against it.
• Efforts include sequencing to enable molecular epidemiological testing, vaccine research, searching for an animal source, and building BL3 and BL4 labs.

S Gene Structure Resembles HIV gp 41
• Spike protein has two regions of alpha-helical structure with heptad repeats, like gp41 and other envelope virus structural proteins.
• Binding of gp120 to target host cells results in conformational changes that result in a hairpin formation, close approximation of viral and host membrane, and fusion.
• Peptides derived from repeat regions can inhibit virus entry and replication of HIV and other viruses; T-20, or Fuzeon, has recently been licensed as a drug.
• Evidence suggests that peptides lock the virus into an intermediate conformation, preventing fusion.

Testing peptides against SARS Coronavirus
• A qualitative CPE assay and a plaque assay in Vero cells have been used to test twelve peptides; five showed varying degrees of antiviral activity.
• Peptide therapeutics are difficult to make and are likely to be injectible rather than oral pills; development is rapid and they are generally not very toxic.
• Activity may be improved upon by optimizing the peptide sequence used.

Previous | Next
Columbia University Digital Knowledge Ventures New York Academy of Sciences Columbia University Mailman School of Public Health National Institute of Allergy and Infectious Diseases United States Department of Health & Human Services
© 2003 Columbia University | Privacy Policy.
This Web site is being provided to you for your own use.
Any copying or distribution of this Web site is prohibited.